Rockville, Feb. 01, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Fact.MR, a market research and competitive intelligence provider, the global benign prostatic hyperplasia (BPH) treatment market is estimated to be worth US$ 47.24 Billion by the end of 2032. From 2022 to 2032, demand for benign prostatic hyperplasia prostate treatment is predicted to grow at a 5% CAGR.
Some of the important factors that influence BPH treatment market growth include increased focus on healthcare, an aging population, deteriorating lifestyle, poor eating habits, hereditary inheritance of the illness, increased research and innovation, and greater availability of therapeutic approaches. Over the projected timeframe, these factors are anticipated to favor demand for BPH homeopathy remedies, BPH relief medicine, and benign prostatic hyperplasia natural remedies.
Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4412
The benign prostatic hyperplasia treatment market in Asia Pacific is broadening at a rapid pace, with a CAGR of 7.3% anticipated during the forecast timeframe, owing to rising demand from medical tourism and severe R&D efforts to ensure long-term supply. Moreover, an increase in the requirement for minimally invasive treatment, an increment in the aging populations, and advancements associated with novel and advanced BPH treatment technologies will all contribute to the growth of the benign prostatic hyperplasia treatment market in Europe.
Key Takeaways from Market Study
- From 2017 to 2021, the global BPH prostate treatment market grew at a CAGR of 3.8%.
- In 2021, the global benign prostatic hyperplasia treatment market revenue accounted for 24% of the global cancer treatment market.
- BPH symptoms are estimated to affect approximately 30 million men worldwide and 14 million men in the United States.
- During the forecast period, specialty clinics are expected to grow at a higher CAGR of more than 6.9%.
- North American regional market is expected to rise 1.4X by 2032.
“The increasing prevalence of benign prostatic hyperplasia, as well as the rising global male aging population, are propelling the expansion of the benign prostatic hyperplasia treatments market. Furthermore, sympathetic stimulation nerve activity, a modified endocrine state, an elevated inflammatory reaction, and oxidative stress all perform a role in the emergence of benign prostatic hyperplasia in obese people.” says a Fact.MR analyst.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4412
Market Competition
Key players in the Benign Prostatic Hyperplasia Treatment market are Abbott Laborites, Allergan plc, Astellas Pharma, Inc., Asahi Kasei Corporation, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer, Inc., Boston Scientific Corporation, Teleflex Incorporated, Endo International plc, Urologix, LLC, LISA Laser, Olympus Corporation, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc.
- In January 2021, PHAREX Health Corporation introduced Pharex Tamsulosin for BPH treatment in collaboration with the Philippine Urological Association (PUA).
- UroLift launched the Advanced Tissue Control (ATC) System in 2020.
- Asahi Kasei Pharma received Chinese approval for Flivas in 2020. (naftopidil).
- Alembic was granted FDA approval for its Abbreviated New Drug Application (ANDA) for Silodosin Capsules 4 mg and 8 mg in 2019.
Major Benign Prostatic Hyperplasia Treatment Service Providers
- Abbott Laboratories
- Allergan Plc.
- Astellas Pharma Inc.
- Asahi Kasei Corporation
- Boehringer Ingelheim GmbH
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Boston Scientific Corporation
- Teleflex Incorporated
- Endo International Plc.
- Urologix LLC
- LISA Laser
- Olympus Corporation
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
Get Full Access of Complete Report:
https://www.factmr.com/checkout/4412
Key Segments Profiled in the Benign Prostatic Hyperplasia Treatment Industry Survey
- By Treatment:
- Drug Class
- Alpha Blockers
- 5-Alpha-reductase Inhibitors (5-ARIs)
- Phosphodiesterase-5 Enzyme Inhibitors
- Others
- Minimally-invasive Surgeries
- Transurethral Resection of the Prostate (TURP)
- Transurethral Incision of the Prostate (TUIP)
- Robotic Surgeries
- Transurethral Microwave Thermotherapy (TUMT)
- Prostatic Urethral Lift
- Others
- Laser Therapy
- Others
- Drug Class
- By End User:
- Hospitals
- Ambulatory Surgical Centres
- Specialty Clinics
- Others
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
More Valuable Insights Available
Fact.MR, in its new offering, presents an unbiased analysis of the chromatography syringes market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2032.
The study divulges essential insights on the market on the basis of, By Drug Classes (Alpha Blockers, 5-Alpha-reductase Inhibitors (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitors), By Minimally-invasive Surgeries, By Laser Therapy, across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa).
Check out more related studies published by Fact.MR Research:
Psychotic Disorder Treatment Market: At present, the global psychotic disorder treatment market accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.
Behavioural Health Treatment Market: The global behavioral health treatment market will grow at a CAGR of 2.9% over the forecast period. Future growth of the global behavior health market will be driven by the increase in telepsychiatry practices in the market.
Gastrointestinal Bleeding Treatment Market: Projections for global gastrointestinal bleeding treatment market indicate a moderate growth rate of 5.1% during the forecast period (2020-2026). The market is set to surpass a value of US$ 849.79 by the end of 2026.
Rare Neurodegenerative Disease Treatment Market: The global rare neurodegenerative disease treatment market size is anticipated to expand at a steady rate to surpass a valuation of US$ 116 billion by 2030-end.
Non-Invasive Aesthetic Treatment Market: The market size of non-invasive aesthetic treatments was around US$ 53.3 Bn in 2021, and it is expected to grow with the compound annual growth rate (CAGR) of 16.5% for the period of 2022 to 2032.
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Analyst: Mr. Shambhu Nath Jha
Email : shambhu@factmr.com
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube
